Lunai Bioworks has secured its first revenue-generating multi-year contract with the U.S. government to deploy its AI platform for chemical threat assessment, marking a significant step in its national security biodefense strategy. The company also formed the Pathfinder Consortium with top institutions like Harvard and Purdue to enhance its biodefense capabilities. Alongside this, Lunai is advancing its precision neurology pipeline targeting diseases like epilepsy and Alzheimer's using AI-driven methods. Additionally, Lunai has initiated legal action against alleged market manipulation to protect shareholder value. Moving forward, the company aims to expand its biodefense platform and neurology programs while pursuing litigation to address stock price suppression.
Vietnam Tech Summit 2026, held August 7-8 at the Computer History Museum in Silicon Valley, is the largest Vietnamese-led tech event in the U.S., focusing on AI's impact on technology careers. The summit offers company tours at Google, Microsoft, Net...
Bumble Inc. is currently valued very low by the market, with price-to-earnings and cash flow ratios near 1.3x, reflecting skepticism despite solid profitability metrics. The company faces significant challenges including a 23% year-over-year drop in ...
Bitcoin fell 8.6% this week, dragging Mantle (MNT) prices down 21.6% amid rising inflation concerns and a sell-off in crypto markets. Mantle broke key long-term support at $0.55, confirming a bearish trend with technical indicators suggesting further...
Pi Network's token is trading near its all-time low around $0.12, down about 95% from its peak. The key challenge is a persistent oversupply due to scheduled token unlocks combined with thin trading liquidity and weak demand. To reach $0.20, a roughl...
The Spear Alpha ETF (SPRX) targets innovative industrial tech stocks and has delivered a 9.2% active return from September 2021 to May 2026, outperforming the IVV benchmark. Its portfolio of 28 stocks shows robust growth, especially a 57.7% forward E...
